[Antibiotic drug minocycline: a potential therapeutic drug for methamphetamine-related disorders].
Accumulating evidence suggests a role of inflammation in the pathophysiology of a number of neuropsychiatric diseases. The second generation antibiotic drug minocycline has potent neuroprotective and anti-inflammatory effects. We reported that minocycline could attenuate behavioral abnormalities and dopaminergic neurotoxicity in mice after administration of methamphetamine or 3,4-methylenedioxymethamphetamine (MDMA). Furthermore, we reported that minocycline was effective in the animal models of schizophrenia. Moreover, a double-blind, placebo-control, cross-over study showed that minocycline was effective in the rewarding effects in healthy human subjects. In this article, we would like to discuss minocycline as a potential therapeutic drug for methamphetamine-related disorders.